Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jan 26:3:1323057.
doi: 10.3389/fdsfr.2023.1323057. eCollection 2023.

Conducting and interpreting disproportionality analyses derived from spontaneous reporting systems

Affiliations
Review

Conducting and interpreting disproportionality analyses derived from spontaneous reporting systems

Paola Maria Cutroneo et al. Front Drug Saf Regul. .

Abstract

Spontaneous reporting systems remain pivotal for post-marketing surveillance and disproportionality analysis (DA) represents a recognized approach for early signal detection. Although DAs cannot be used per se as a standalone approach to assess a drug-related risk and cannot replace clinical judgment in the individual patient, their role remain irreplaceable for rapid detection of rare and unpredictable adverse drug reactions with strong drug-attributable component (e.g., designated medical events), especially when developed by a multidisciplinary team and combined with a careful case-by-case analysis (individual inspection of reports for causality assessment or to uncover reporting patterns and clinical features). In the recent past, a remarkable increase in publications of pharmacovigilance studies using DAs was observed, albeit the quality was debated: several publications contained "spin", namely, misinterpretation of results to infer causality, calculate incidence, or provide risk stratification, which may ultimately result in unjustified alarm. The development of dedicated Guidelines by the international READUS-PV project (https://readus-statement.org/) will allow reproducible and transparent publication of accurate DAs, thus supporting their real transferability and exploitation by regulators and clinicians. This review offered a perspective on methodological aspects (and understanding) of DAs, their rationale, design, reporting, and interpretation.

Keywords: SDR; adverse drug reactions; disproportionality; disproportionality analyses; signal detection; spontaneous reporting database.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The authors declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.

Figures

FIGURE 1
FIGURE 1
Flowchart of signal management, simplified and applied to reports of suspected ADRs. For a complete overview of the process, please see Good Vigilance Practices Module IX (European Medicine Agency, 2017). Throughout the phases of signal management, signals are continuously prioritized within signal prioritization. Shape borders in black indicate the steps that are most relevant to signals of disproportionate reporting.

References

    1. Agbabiaka T. B., Savović J., Ernst E. (2008). Methods for causality assessment of adverse drug reactions: a systematic review. Drug Saf. 31 (1), 21–37. 10.2165/00002018-200831010-00003 - DOI - PubMed
    1. Al-Aqeel S. A. (2012). Evaluation of medication package inserts in Saudi Arabia. Drug Healthc. Patient Saf. 4 (1), 33–38. 10.2147/DHPS.S29402 - DOI - PMC - PubMed
    1. Al-Azzawi F., Mahmoud I., Haguinet F., Bate A., Sessa M. (2023). Developing an artificial intelligence-guided signal detection in the food and drug administration adverse event reporting system (FAERS): a proof-of-concept study using galcanezumab and simulated data. Drug Saf. 46 (8), 743–751. 10.1007/s40264-023-01317-0 - DOI - PMC - PubMed
    1. Alkabbani W., Gamble J.-M. (2023). Active-comparator restricted disproportionality analysis for pharmacovigilance signal detection studies of chronic disease medications: an example using sodium/glucose cotransporter 2 inhibitors. Br. J. Clin. Pharmacol. 89 (2), 431–439. 10.1111/bcp.15178 - DOI - PubMed
    1. Alloza J. L., Lasagna L. (1983). A comparison of drug product information in four national compendia. Clin. Pharmacol. Ther. 33 (3), 269–277. 10.1038/clpt.1983.32 - DOI - PubMed

LinkOut - more resources